|
|
| |
Central nervous system (CNS) disorders are major causes of mortality
and disability. Because they are afflicting an increasing number of
people, the World Health Organisation have indicated that they will
become the major medical need of the 21st century. Whilst CNS drugs
generate in excess of $50 billion in sales and constitute the fastest
growing therapeutic segment of the pharmaceutical market, treatments
for most CNS disorders are either absent or sub-optimal, and compared
to other therapeutic areas it takes longer to get a CNS drug to market
(12-15 years as opposed to 10-12 years for non-CNS drugs) and because
of a higher attrition rate, the probability of success is markedly
lower – because the
attrition rate is higher.
The challenge is to deliver higher quality CNS drug candidates faster |
| |
|
|
